Gregory J Eustace1, Gil Y Melmed2. 1. F Widjaja Inflammatory Bowel and Immunobiology Research Institute, Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. 2. F Widjaja Inflammatory Bowel and Immunobiology Research Institute, Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. Gil.Melmed@cshs.org.
Abstract
PURPOSE OF REVIEW: To review recent advances in the treatment of Crohn's disease. RECENT FINDINGS: Several key advances are highlighted, including the increasing role of treatment algorithms and where new therapies can be used most effectively, the appropriate use of therapeutic drug monitoring, optimal management of post-surgical patients, and the role of multi-disciplinary clinics. The last several years have seen a number of exciting developments in the field of Crohn's therapy. This review covers research advances including updated treatment algorithms focusing on identifying patient risk as well as the role of drug monitoring in managing the disease. We also review the optimal management of post-surgical patients as well as new biologics and biosimilars. Finally, we describe innovations in care delivery including multi-disciplinary clinics and emerging evidence from developing therapeutics.
PURPOSE OF REVIEW: To review recent advances in the treatment of Crohn's disease. RECENT FINDINGS: Several key advances are highlighted, including the increasing role of treatment algorithms and where new therapies can be used most effectively, the appropriate use of therapeutic drug monitoring, optimal management of post-surgical patients, and the role of multi-disciplinary clinics. The last several years have seen a number of exciting developments in the field of Crohn's therapy. This review covers research advances including updated treatment algorithms focusing on identifying patient risk as well as the role of drug monitoring in managing the disease. We also review the optimal management of post-surgical patients as well as new biologics and biosimilars. Finally, we describe innovations in care delivery including multi-disciplinary clinics and emerging evidence from developing therapeutics.
Authors: Geert D'Haens; Filip Baert; Gert van Assche; Philip Caenepeel; Philippe Vergauwe; Hans Tuynman; Martine De Vos; Sander van Deventer; Larry Stitt; Allan Donner; Severine Vermeire; Frank J Van De Mierop; Jean-Charles R Coche; Janneke van der Woude; Thomas Ochsenkühn; Ad A van Bodegraven; Philippe P Van Hootegem; Guy L Lambrecht; Fazia Mana; Paul Rutgeerts; Brian G Feagan; Daniel Hommes Journal: Lancet Date: 2008-02-23 Impact factor: 79.321
Authors: Miguel Regueiro; Brian G Feagan; Bin Zou; Jewel Johanns; Marion A Blank; Marc Chevrier; Scott Plevy; John Popp; Freddy J Cornillie; Milan Lukas; Silvio Danese; Paolo Gionchetti; Stephen B Hanauer; Walter Reinisch; William J Sandborn; Dario Sorrentino; Paul Rutgeerts Journal: Gastroenterology Date: 2016-03-03 Impact factor: 22.682
Authors: Reena Khanna; Brian Bressler; Barrett G Levesque; Guangyong Zou; Larry W Stitt; Gordon R Greenberg; Remo Panaccione; Alain Bitton; Pierre Paré; Séverine Vermeire; Geert D'Haens; Donald MacIntosh; William J Sandborn; Allan Donner; Margaret K Vandervoort; Joan C Morris; Brian G Feagan Journal: Lancet Date: 2015-09-03 Impact factor: 79.321
Authors: Bjoern Titz; Raffaella M Gadaleta; Giuseppe Lo Sasso; Ashraf Elamin; Kim Ekroos; Nikolai V Ivanov; Manuel C Peitsch; Julia Hoeng Journal: Int J Mol Sci Date: 2018-09-15 Impact factor: 5.923